In response to RFA-DK-09-504 we present a plan for future activities of the Coordinating Center for the Beta Cell Biology Consortium (BCBC). This consortium, which was initially launched in September 2001 then renewed in 2005, brings a team-oriented approach to studies necessary to learn how to regenerate or replace pancreatic beta cells that are either destroyed or damaged by Type 1 or Type 2 diabetes. The Coordinating Center plays a vital role in the consortium by 1) organizing investigator meetings and retreats, 2) maintaining the BCBC website and reagent databases, 3) overseeing BCBC core facilities, 4) providing advanced bio/informatics applications, 5) managing special funding programs, 6) providing various types of administrative support, and 7) facilitating interactions with other NIH-sponsored Centers and Consortia. During the next cycle of the BCBC the Coordinating Center will 1) continue to perform many ongoing operations, 2) adapt to changes in the scientific focus and new participants, and 3) improve the website in a way to facilitate team science and sharing of unpublished knowledge and reagents.
Type 1 and Type 2 diabetes cause significant morbidity and mortality and thus have an adverse economic impact. Both diseases are characterized by the destruction or dysfunction of insulin-secreting pancreatic beta cells. This application will coordinate activities among a team of scientists in order to develop new, cell-based replacement therapies that hold promise for achieving better glucose control than is currently possible.
|Azzopardi, Stephanie; Pang, Sharon; Klimstra, David S et al. (2016) p53 and p16(Ink4a)/p19(Arf) Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells. Neoplasia 18:610-617|
|Arda, H Efsun; Li, Lingyu; Tsai, Jennifer et al. (2016) Age-Dependent Pancreatic Gene Regulation Reveals Mechanisms Governing Human Î² Cell Function. Cell Metab 23:909-20|
|Damond, Nicolas; Thorel, Fabrizio; Moyers, Julie S et al. (2016) Blockade of glucagon signaling prevents or reverses diabetes onset only if residual Î²-cells persist. Elife 5:|
|Poudel, Ananta; Fowler, Jonas L; Zielinski, Mark C et al. (2016) Stereological analyses of the whole human pancreas. Sci Rep 6:34049|
|Saunders, Diane; Powers, Alvin C (2016) Replicative capacity of Î²-cells and type 1 diabetes. J Autoimmun 71:59-68|
|Clayton, Hannah W; Osipovich, Anna B; Stancill, Jennifer S et al. (2016) Pancreatic Inflammation Redirects Acinar to Î² Cell Reprogramming. Cell Rep 17:2028-2041|
|Bechard, Matthew E; Bankaitis, Eric D; Hipkens, Susan B et al. (2016) Precommitment low-level Neurog3 expression defines a long-lived mitotic endocrine-biased progenitor pool that drives production of endocrine-committed cells. Genes Dev 30:1852-65|
|Delong, Thomas; Wiles, Timothy A; Baker, Rocky L et al. (2016) Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351:711-4|
|Boortz, Kayla A; Syring, Kristen E; Dai, Chunhua et al. (2016) G6PC2 Modulates Fasting Blood Glucose In Male Mice in Response to Stress. Endocrinology 157:3002-8|
|Hoang, Danh-Tai; Hara, Manami; Jo, Junghyo (2016) Design Principles of Pancreatic Islets: Glucose-Dependent Coordination of Hormone Pulses. PLoS One 11:e0152446|
Showing the most recent 10 out of 109 publications